Haynes and Boone represented NRX Pharmaceuticals, Inc. in the offering, and Sichenzia Ross Ference Carmel represented EF Hutton. NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), (“NRx Pharmaceuticals” or...
NRx Pharmaceuticals’ $1.5 Million Common Stock Offering
Firefly Neuroscience’s Merger with WaveDancer
Haynes and Boone, LLP is representing Firefly Neuroscience, Inc. in the transaction, and Greenberg Traurig is representing WaveDancer, Inc. Firefly Neuroscience, Inc. (“Firefly”) announced it has...
LadRx’s Royalty Purchase Agreement with XOMA
Haynes and Boone, LLP represented LadRx Corporation, while Gibson, Dunn & Crutcher LLP represented XOMA (US) LLC. LadRx announced that it has transferred the royalty and milestone...
Enveric Biosciences’ Acquisition of MagicMed Industries
Haynes and Boone represented Enveric Biosciences in the transaction. Enveric Biosciences (NASDAQ: ENVB) executed its acquisition of MagicMed Industries Inc., a privately-held biotechnology company focused on...
Gold Royalty’s $90 Million Initial Public Offering
Haynes and Boone represented Gold Royalty Corp. in the offering. Gold Royalty Corp. executed its $90 million initial public offering and listing on the NYSE American....